Purpose: This study was designed as a multicenter, randomized, open-label study to evaluate the efficacy and tolerability of Clotinab TM . We expected to obtain same results as with ReoPro Ⓡ in improving ischemic cardiac complications in high-risk patients who were about to undergo percutaneous coronary intervention (PCI). Patients and Methods: Patients of 19 -80 years of age with acute coronary syndrome (ACS) who were about to undergo PCI were enrolled. After screening and confirmation of eligibility, patients were randomly assigned to different groups. Clotinab TM was given to 84 patients (58.7 ± 10.6 years, M : F = 68 : 16) and ReoPro Ⓡ (59.0 ± 10.5 years, M : F = 30 : 10) was given to 40 patients before PCI. The primary efficacy endpoint was the onset of major adverse cardiac event (MACE) within 30 days from day 1. The tolerability endpoints were assessed based on bleeding, thrombocytopenia, change in Hb/Hct, human antichimetric antibody development, and adverse events. Results: The number of Clotinab TM patients experiencing MACE was 0 out of 76 per protocol (PP) patients. The MACE rate was 0%, and its 95% exact CI was [0.00 -4.74%]. A major bleeding event developed in 3 patients in the ReoPro Ⓡ group. The probability of MACE onset in Clotinab TM was estimated to be less than 5%. There was no clinically significant result in tolerability variables. Conclusion: Clotinab TM is an effective and safe medicine in preventing ischemic cardiac complications for high-risk patients who will receive PCI.
INTRODUCTION
Platelet-mediated thrombosis accounts for the pathophysiology of acute coronary syndrome (ACS). 1, 2 In the treatment of ACS, intravenous platelet glycoprotein (GP) IIb/IIIa receptor antagonists for platelet aggregation may reduce the risk of ischemic complications. [3] [4] [5] [6] [7] Therefore, in the management of ACS, platelet GP IIb/IIIa receptor inhibitors have been developed as a promising therapy for the reduction of coronary events and the improvement of clinical outcomes. Abciximab, a platelet GP IIb/IIIa receptor blocker, was developed by Coller in 1985 and named 7E3. 8 Abciximab is a chimeric human monoclonal antibody and binds to platelet surface GP IIb/IIIa receptors competitively with adhesive molecules, such as fibrinogen and von Willebrand factor, and blocks the final stage of platelet aggregation. 9 Clotinab TM a product manufactured by ISU ABXIS Co., Ltd, was produced by inserting antiplatelet GP IIb/IIIa DNA into a Chinese hamster's ovary cell. Since it contains the same active ingredient as ReoPro Ⓡ , Clotinab TM is expected to have the same efficacy as ReoPro Ⓡ as a platelet GP IIb/IIIa receptor inhibitor. Therefore, the aim of this trial was to evaluate the efficacy and tolerability of Clotinab TM as an investigational drug and prevent ischemic cardiac events in high-risk patients scheduled to undergo PCI.
PATIENTS AND METHODS

Patients
Korean men and women between 19 -80 years of age with ACS meeting 1 of the following conditions and who were scheduled to undergo PCI were enrolled: 1) Patients with ischemic ST change in the electrocardiogram as well as refractory to drug treatment in resting phase or with recurrent angina pectoris; 2) Post-infarction angina patients within 7 days from acute myocardial infarction (AMI) attack refractory to drug treatment with ischemic ST change in the electrocardiogram; 3) Acute Q-Wave myocardial infarction (MI) within 12 hours after the attack that required direct intervention procedures; 4) Acute Q-wave myocardial infarction within 12 hours after the attack that required another rescue intervention after failure to thrombolytic therapy; and 5) Classification of vascular lesions according to the American College of Cardiology/American Heart Association (ACC/AHA) criteria defined by angiography. 10 -Two type B lesion characteristics -One type C lesion characteristic -Females aged over 65 with one type B lesion characteristic -Diabetes with one type B lesion characteristic
Exclusion criteria
Patients with any of the following were excluded from the study: those in which PCI could not be performed within 24 hours from receiving the investigational product or occlusion of the left main coronary artery was ≥ 50% and bypass surgery was necessary. In addition, subjects with a culprit lesion in the bypass graft; history of major surgery, trauma, or retinal hemorrhage; significant gastrointestinal or genitourinary bleeding in the previous 6 weeks; cerebrovascular attack in the past 2 years or a cerebrovascular attack with a significant residual neurological deficit were excluded. Patients who required oral anticoagulants during the trial; those who had been administrated oral anticoagulants in the past 7 days; severe uncontrollable hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 100 mmHg); thrombocytopenia (< 100,000 cells/mL); hypersensitivity to the test drug or the murine protein; history of hypersensitivity; intracranial neoplasm, arteriovenous malformation; aneurysm; history or diagnosis of vasculitis; renal insufficiency (the level of serum creatinine was 2 times higher than the upper limit of normal of each center); or hepatic disorder (AST, ALT was three times higher than the upper limit of normal) were excluded. Pregnant women, alcoholics, drug abusers, patients who could not take anti-platelet drugs, and those who might have died of causes other than cardiac disease during the trial were also removed from the study. were recruited over two stages, the patients who were receiving Clotinab TM were considered as one group because there was no time break between the first and second stage and no protocol change between stages. During the initial screening, patients underwent complete physical examinations, baseline electrocardiograms, and laboratory assessments. They were randomly assigned into 2 groups according to a computer-generated allocation schedule. A randomization list was made using a block randomization method. To create a 4 : 3 allocation ratio between the treatment and control groups, a block of size 7 was used for each center. The size of the block was not specified in the protocol or known to investigators.
Study design
After the screening and confirmation of the eligibility of patients, those who signed written consent forms were randomly assigned to one of the groups prior to the procedure, administration of the investigational product, and treatment by PCI on day 1. One group received 0.25 mg/kg of Clotinab TM IV bolus 10 minutes to 6 hours prior to PCI, followed by an infusion of 0.125 mg/kg/ min (Max 10 μg/min) dissolved in sterile saline of 0.9% or 5% dextrose followed for 12 hours. The other group received 0.25 mg/kg of ReoPro Ⓡ IV bolus 10 minutes to 6 hours prior to PCI, followed by an infusion of 0.125 mg/kg/min (Max 10 μg/ min) dissolved in sterile saline of 0.9% or 5% dextrose followed for 12 hours. After the procedure, subjects remained in the intensive care units for observation. At least 2 hours before PCI in both groups, 200 mg of aspirin was administered orally, followed by oral administration of 100 mg/ day. In addition to aspirin, a loading dose of 300 mg and maintenance dose of 75 mg/day of clopidogrel were given. On day 30 after discharge, patients visited the hospital for safety and efficacy assessments. During the clinical visit, subjects were assessed by all clinical and laboratory measures, to unravel, the likelihood of a causal relationship between the study and the study drug ("definitely related", "probably related", "possibly related", "probably not related", "definitely not related", and "unknown"), and they were categorized by the intensity of clinical adverse experiences (CAEs). The institutional review board and ethics committee at each participating center approved the protocol, and written consent forms were obtained from all patients.
Efficacy assessments
The primary efficacy endpoint was the onset of MACE within 30 days from the study drug administration following PCI. MACE included death related to heart disease, recurrence of MI, and emergency revascularization. We classified the cause of death to either "cardiovascular causes" or "non-cardiovascular causes" (If non-cardiovascular causes could not clearly be established, the cause of death was classified to "cardiovascular causes"). The recurrence of MI was categorized as ST-elevation MI (STEMI) or non-ST-elevation MI (NSTEMI) [NSTEMI; CK-MB > 3 times the upper limit of normal value and increase of > 50% in the second sample over the first sample when two samples were collected at two different times]. A return to the catheterization laboratory for emergency revascularization to treat recurrent ischemia was considered as a primary event. A scheduled PCI (staged procedures) nor elective surgery to treat pre-existing multivessel disease was considered primary events. The secondary efficacy endpoint was a change in the electrocardiogram [New change in electrocardiogram was decided by investigator's decision about the ECG result], indicating myocardial ischemia.
Tolerability assessments
Tolerability endpoints were assessed by bleeding, thrombocytopenia, changes in Hb/Hct, HACA (human antichimetric antibody) development, and adverse events. (1) Bleeding: According to TIMI criteria, 11 bleeding was categorized into "major bleeding". "minor bleeding", or "insignificant bleeding". (2) Thrombocytopenia: The details were described for patients whose platelet count was < 100.000 and platelet count decreased by ≥ 25% compared to baseline count. (3) Change of Hb/Hct: (4) HACA development: Frequency and proportion were presented to patients showing a positive response to HACA development by group. (5) Adverse events: All adverse events were coded. Frequency and proportion by these codes were generated in 2 groups. The frequency was calculated by group for adverse events that were related to the study drug ("definite", "probable", "possible") and not ("improbable", "none", "unknown"). Frequency and proportion (95% exact CI) were presented for the number of adverse event and the number of subjects in which adverse events occurred at least once.
Manufacturing process of Clotinab
TM
The active substance abciximab is produced in recombinant Chinese Hamster Ovary (CHO) cells using a serum-free media. The master cell bank (MCB), working cell bank (WCB), and end of production cells were sufficiently characterized. The MCB and WCB were adopted to grow in serum-free media. The manufacturing process of the active ingredient starts with the thawing and expansion of cells from the MCB or WCB derived from the MCB. Cells were expanded using a flask and fermenters. After harvesting, different chromatographic steps were used for purification. With affinity chromatography, unwanted protein and potential endotoxin contaminants were removed. Cation exchange chromatography removes antibody aggregates and fragment and CHO impurities. Anion exchange chromatography is intended to separate DNA, endotoxins, and retroviruses if present. With hydrophobic interaction, the chromatography removes antibody aggregates and fragments and CHO proteins.
Statistical analysis
A 1-sided significance test was applied to the primary efficacy endpoint at α = 0.05. All other significance tests were 2-sided at α = 0.05, and the efficacy analysis was the PP analysis. All statistical analyses were carried out by SAS Ⓡ (Version 9.1, SAS institute, Cary, NC, USA). Exact confidence intervals were computed by StatXact (version 4.0, Cytel Software Corp). Continuous variables were compared using t-test or Wilcoxon rank sum test by treatment group. Categorical variables were compared using chi-square test or Fisher's exact test. For the primary endpoint, a non-inferiority analysis of the difference in MACE from baseline to day 30 between both study groups was assessed. 
RESULTS
Patient characteristics
A total of 124 patients were screened for this trial at 3 medical centers. First, 31 patients were given Clotinab TM treatment without randomization.
Afterward, 93 patients were admitted and randomized into the Clotinab TM (53) and ReoPro Ⓡ (40) groups. Out of the 124 subjects screened, one ITT, intention-to-treated; SBP, systolic blood pressure; DBP, diastolic blood pressure; T. cholesterol, total cholesterol. subject was excluded before the treatment started, because the patient was found to be ineligible. After the study drugs were administered and PCI was performed on the 123 patients, one Clotinab TM subject withdrew consent and left the trial. The disposition status of 124 patients is shown in Fig. 1 Ⓡ : 36), PP analysis was the main method used to evaluate the efficacy of the drug and FAS analysis was used to determine the tolerability of the study drug. Table 1 gives the general characteristics of patients included in the study. The distribution of subjects by disease entity is shown in Table 2 . There was no significant difference between the two study groups.
Efficacy results
The primary efficacy endpoint was the onset of MACE within 30 days from the study drug administration following PCI. 
Tolerability results
Based on TIMI criteria, no major bleeding occurred in Clotinab TM patients, but 3 subjects (7.50%) experienced major bleeding on ReoPro Ⓡ . The number of subjects with minor bleeding was 11 (13.25%) for Clotinab TM and 5 (12.50%) for ReoPro Ⓡ . The number of subjects with clinically insignificant bleeding was 11 (13.25%) for Clotinab TM and 9 (22.50%) for ReoPro Ⓡ . Based on TIMI criteria, the number of patients with overall bleeding showed no significant difference between Clotinab TM and ReoPro Ⓡ at each time point (Table 4) . However, a number of patients with major bleeding showed significant and PURSUIT trial. 6 Therefore, the use of GP IIb/IIIa inhibitor has become standard therapy for PCI in high-risk patients. The ACC/AHA recommend the use of platelet GP IIb/IIIa inhibitors in patients undergoing PCI. 19 The representative platelet GP IIb/IIIa receptor blockers currently used in clinical practice include abciximab (ReoPro Ⓡ ), which is a chimeric human-murine monoclonal antibody fragment; eptifibatide (Integrilin), which is a peptide; and Tirofiban (Aggrastat Ⓡ ) and Lamifiban, which are peptidomimetics. 5, 9, 16, 18, [20] [21] [22] The most potent antithrombotic effect has been documented with ReoPro Ⓡ , because it has a prolonged half-life and binds to the vitronectin receptor (found on endothelial and smooth-muscle cells). 23, 24 Therefore, ReoPro Ⓡ has the potential to influence the adhesion of platelets with endothelial cells and platelets with white cells. However, the selection of platelet GP IIb/IIIa receptor blockers is often based on the clinician's preference and cost consideration. Because of its relatively high cost, the use of ReoPro Ⓡ is not an option for some patients. There are reports on the economics of GP IIb/IIIa inhibitor therapy. The PRICE (Prairie ReoPro Ⓡ Versus Integrilin Cost Evaluation) trial evaluated the differences between groups and concluded that eptifibatide was associated with lower in-hospital and 30-day costs compared to ReoPro Ⓡ . 25 By comparing abciximab and eptifibatide, the PRICE study noted significant differences in hospitalization and acquisition costs despite comparable tolerability and effectiveness. 26 There are unequivocal clinical benefits in using GP IIb/IIIa inhibitors to reduce the ischemic complications of PCI. TARGET 27 demonstrated the benefit of abciximab, in ischemic outcomes ofpatients treated by PCI compared to tirofiban. Moreover, the meta-analysis on the different GP IIb/IIIa receptor blockers suggests clinical differences among these drugs. 28 Because the economics of the GP IIb/IIIa inhibitor therapy are closely linked to drug efficacy and tolerability, the development of GP IIb/IIIa receptor blocker, which is not only biocompatible to ReoPro Ⓡ in efficacy and tolerability but also low in cost, may be an affordable option. Clotinab TM , shown to be effective and safe in this study, may be used, in clinical practice, as a good substitute for ReoPro Ⓡ because of its low cost. In conclusion, the probability of MACE onset in patients who use Clotinab TM is estimated to be less than 5%. There was no significant outcome in tolerability variables. Therefore, clotinab TM is an effective medicine in preventing ischemic heart complications for high-risk patients who undergo PCI.
